I
688253
vs
S
Shanghai Composite
Over the past 12 months, Innovita Biological Technology Co Ltd has underperformed Shanghai Composite, delivering a return of +9% compared to the Shanghai Composite's +23% growth.
Stocks Performance
688253 vs Shanghai Composite
Performance Gap
688253 vs Shanghai Composite
Performance By Year
688253 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Innovita Biological Technology Co Ltd
Glance View
Innovita Biological Technology Co., Ltd. engages in the research and development, production, and sale of point-of-care testing rapid diagnostic products. The company is headquartered in Beijing, Beijing and currently employs 439 full-time employees. The company went IPO on 2022-07-28. The firm's main products include novel coronavirus (2019-nCoV) neutralizing antibody detection kits using colloidal gold, quantum dot fluorescence immunochromatography and chemiluminescence techniques, and respiratory pathogen detection products, such as whole blood respiratory quintuple detection card, influenza virus triple detection card, virus serum quintuple detection card, respiratory pathogen nine indirect immunofluorescence kit, and others.